Astria, Jmp

JMP Securities starts Astria Therapeutics stock at Market Outperform
JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a price target of $26.00. The stock, currently trading at $7.49, sits near its 52-week low of $7.
Astria Therapeutics (NASDAQ:ATXS) Rating Increased to Strong-Buy at Citizens Jmp
Citizens Jmp upgraded shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) to a strong-buy rating in a report published on Friday,Zacks.com reports. Other equities analysts have also recently issued research reports about the company.
Astria Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Jonathan Wolleben initiated coverage of Astria Therapeutics (ATXS) with an Outperform rating and $26 price target
JMP Securities starts Astria Therapeutics stock with $26 target
Astria Therapeutics' focus on leveraging its half-life extension technology to create long-acting mAbs targeting derisked targets in established markets has positioned the company favorably in the eyes of JMP Securities.
JMP Securities Initiates Coverage of Astria Therapeutics (ATXS) with Market Outperform Recommendation
Fintel reports that on January 31, 2025, JMP Securities initiated coverage of Astria Therapeutics (NasdaqGM:ATXS) with a Market Outperform recommendation. Analyst Price Forecast Suggests 244.82% Upside As of January 29,
Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present quality ...
Buy Rating for Astria Therapeutics: Promising Prospects in HAE and Atopic Dermatitis Markets
Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...
Business Wire1mon
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced ...
CNN3y
Astria Therapeutics, Inc.
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary ...
Morningstar1mon
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 58,650 ...
Business Wire1mon
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced ...